ArticleJournal of pharmacokinetics and pharmacodynamics2017

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.

Kumar Kandadi Muralidharan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.